- Home
- PMF vs CLLS Comparison
PMF vs CLLS Comparison
Compare PMF & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMF
- CLLS
- Stock Information
- Founded
- PMF 2001
- CLLS 1999
- Country
- PMF United States
- CLLS France
- Employees
- PMF N/A
- CLLS N/A
- Industry
- PMF Finance/Investors Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- PMF Finance
- CLLS Health Care
- Exchange
- PMF Nasdaq
- CLLS Nasdaq
- Market Cap
- PMF 249.4M
- CLLS 240.2M
- IPO Year
- PMF N/A
- CLLS 2007
- Fundamental
- Price
- PMF $9.87
- CLLS $1.95
- Analyst Decision
- PMF
- CLLS Buy
- Analyst Count
- PMF 0
- CLLS 2
- Target Price
- PMF N/A
- CLLS $8.00
- AVG Volume (30 Days)
- PMF 61.3K
- CLLS 22.5K
- Earning Date
- PMF 01-01-0001
- CLLS 11-04-2024
- Dividend Yield
- PMF 5.36%
- CLLS N/A
- EPS Growth
- PMF N/A
- CLLS N/A
- EPS
- PMF N/A
- CLLS N/A
- Revenue
- PMF N/A
- CLLS $19,635,000.00
- Revenue This Year
- PMF N/A
- CLLS $271.02
- Revenue Next Year
- PMF N/A
- CLLS $33.48
- P/E Ratio
- PMF N/A
- CLLS N/A
- Revenue Growth
- PMF N/A
- CLLS N/A
- 52 Week Low
- PMF $7.69
- CLLS $0.96
- 52 Week High
- PMF $10.56
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- PMF 46.50
- CLLS 37.89
- Support Level
- PMF $10.03
- CLLS $1.95
- Resistance Level
- PMF $10.18
- CLLS $2.06
- Average True Range (ATR)
- PMF 0.14
- CLLS 0.10
- MACD
- PMF -0.04
- CLLS -0.01
- Stochastic Oscillator
- PMF 0.79
- CLLS 18.92
About PMF PIMCO Municipal Income Fund
PIMCO Municipal Income Fund is a closed-end management investment company. Its primary investment objective is to seek to provide current income exempt from federal income tax. The fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal income tax.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.